Linezolid
Download
1 / 45

LINEZOLID - PowerPoint PPT Presentation


  • 1021 Views
  • Uploaded on

LINEZOLID. The discovery and clinical development of effective antibiotics is most remarkable achievement over the past 60 years. Since the introduction of the sulphonamides in 1936, researchers have developed a range of antibiotic classes.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'LINEZOLID' - nicki


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

Linezolid

  • .

  • Since the introduction of the sulphonamides in 1936, researchers have developed a range of antibiotic classes.


Linezolid


Linezolid

  • Approved in 2000 by the US FDA.

  • .

  • Linezolid has a unique mechanism of antibacterial action.


Linezolid

  • . antibacterial agents.


Linezolid


Linezolid

  • .

  • It is approved US FDA in adults (April 2000) and children (December 2002) for the treatment of Gram Positive bacteria.


Linezolid

  • It disrupts bacterial growth by inhibiting likely and has not been shown till date.

  • the initiation process in protein synthesis.

  • It binds to a site on the bacterial 23s

  • ribosomal RNA of the 50s subunit,

  • preventing the formation of functional 70s

  • initiation complex which is an essential

  • component of the bacterial translation

  • process.


Linezolid

  • This site of inhibition process occurs likely and has not been shown till date.

  • earlier in the initiation process than

  • other protein synthesis inhibitors

  • that interfere with the elongation

  • process.


Linezolid

  • Absorption: likely and has not been shown till date. Well absorbed orally irrespective of timing of meal

  • .

  • Bioavailability: 100%


Linezolid

  • Half Life: likely and has not been shown till date.

  • Preterm neonate < 1 week: 5.6 hrs.

  • Term neonate < 1 week: 3 hrs.

  • Term neonate > 1 week: 1.5 hrs.

  • Infants: 1.8 hrs

  • Children: 3 + 1.1 hrs

  • Adolescent: 4.1 hrs

  • .


Linezolid

  • .

  • Distributes readily to well perfused area


Linezolid

  • .

  • A) aminoethoxyacetic acid

  • (B) hydroxyethyl glycine


Linezolid

  • .

  • Approximately 30% of the dose appears in urine as Linezolid, 40% as metabolite B and 10% as metabolite A


Linezolid

  • Enterococcus faecium (vancomycin

  • resistant strains only)

  • Staphylococcus aureus ( including

  • methicillin resistantstrain)

  • Streptococcus agalactiae

  • Streptococcus pneumoniae

  • ( penicillin susceptible strains only)

  • Strptococcus pyrogenes

  • .


Linezolid

Enterococcus faecalis (including vancomycin-resistan strains)

Enterococcus faecalis (vancomycin-susceptible strains)

Staphylococcus epidermidis (including methicillin- resistant strains)

Staphylococcus haemolyticus.

Streptococcus pneumoniae (penicillin-resistant strains)

Viridans group streptococci

  • .

  • Aerobic and facultative Gram-negative microorganisms

Pasteurella multocida


Linezolid

  • Vancomycin total clearance. -Resistant Enterococcus faecium

  • infections, including cases with concurrent bacteremia

  • Nosocomial pneumonia caused by staphylococcus aureus

  • (methicillin susceptible and resistant strains), or

  • streptococcus pneumoniae (penicillin susceptible strains).

  • .

  • Combination therapy may be clinically indicated if the

  • documented or presumptive pathogens include

  • Gram- negative organisms.


Linezolid

  • .

  • Uncomplicated skin and skin structure

  • infections caused by staphylococcus aureus

  • (methicillin-susceptible only) or streptococcus

  • pyogenes


Linezolid

  • Community-acquired pneumonia caused staphylococcus aureus (methicillin-susceptible and resistant strains), streptococcus pyogenes, or streptococcus agalactiae

  • by Streptococcus pneumoniae (penicillin-susceptible strains only),including cases with concurrent bacteremia, or staphylococcus aureus (methicillin-susceptible strains).

  • .


Linezolid

  • . staphylococcus aureus (methicillin-susceptible and resistant strains), streptococcus pyogenes, or streptococcus agalactiae


Linezolid

  • . staphylococcus aureus (methicillin-susceptible and resistant strains), streptococcus pyogenes, or streptococcus agalactiae


Linezolid

  • CBC, Hb & Platelet count: particularly in patients who are at increased risk for bleeding, patients with pre-existing thrombocytopenia or Myelosuppression or concomitant medications that decrease platelet count or function or produce bone marrow suppression and in patient requiring more than 2 weeks therapy.

  • .

  • Number and type of stools /day for diarrhea


Linezolid

  • Well tolerated by most patients. at increased risk for bleeding, patients with pre-existing thrombocytopenia or Myelosuppression or concomitant medications that decrease platelet count or function or produce bone marrow suppression and in patient requiring more than 2 weeks therapy.

  • Same in children & adults

  • The most common adverse effects are:

  • Myelosuppression (1 to 10%) including anemia, pancytopenia,

  • leucopenia & thrombocytopenia

  • Diarrhea (4 to 8%),

  • Headache, Insomnia, Dizziness (2 to 6%)

  • Nausea, vomiting (1 to 3.7%),

  • Altered taste or tongue discoloration (1 to 2%)

  • Transient elevation in liver function test (1 to 2%).

  • Pseudo membranous colitis


Linezolid

  • . at increased risk for bleeding, patients with pre-existing thrombocytopenia or Myelosuppression or concomitant medications that decrease platelet count or function or produce bone marrow suppression and in patient requiring more than 2 weeks therapy.


Linezolid

  • .


Linezolid

  • .



Linezolid

  • .

  • Limit intake of Tyramine containing

  • foods to less than 100 mg/meal


Linezolid

  • Linezolid is not an inducer of hepatic insufficiency.

  • cytochrome p450 (CYP).

  • Therefore no CYP 450 induced

  • drug interactions are expected.

  • So the drugs like Warfarin and

  • Phenytoin can be given without

  • dose alteration.

  • .


Linezolid

  • Monoamine Oxidase inhibiter: hepatic insufficiency.

  • It is a reversible non selective inhibitor of monoamine oxidase. Therefore, it has potential for interaction with adrenergic and serotonergic agents such

  • as Tricyclic antidepressants, Detromethorpan and

  • Trazodone.

  • .


Linezolid

  • Store reconstituted preparation at room hepatic insufficiency.

  • temperature and use within 21 days.

  • Store infusion bag in over wrap until

  • ready to use. The yellow color of

  • infusion solution may intensify over

  • time without adversely affecting the

  • potency.

  • Store at room temperature & protect

  • from light.

  • Injection is compatible with D5, RL, NS


Linezolid

  • Avoid excessive amount of Tyramine hepatic insufficiency.

  • containing foods; Red wine, Aged

  • cheese, Smoked or pickled fish, Beef

  • or chicken liver, dried sausage, fava

  • or broad bean.

  • Notify in case of persistent or

  • worsening of symptoms of infection,

  • diarrhea, nausea or vomiting.

  • Complete course of therapy even if

  • symptoms improve.

  • .


Linezolid

  • -Injection: 200mg (100 ml) hepatic insufficiency.

  • 400mg (200 ml)

  • 600mg (300 ml)

  • Infuse over 30-120 mins. Do not infuse

  • with any other medication. Flush IV

  • line before & after infusion with

  • compatible solution.

  • - Suspension: Dry powder 20mg/ml

  • Gently invert bottle 3-5 times. Do not

  • shake.

  • - Tablet: 400mg, 600mg


Linezolid

  • Linospan (Cipla) hepatic insufficiency.

  • Linox (Unichem)

  • Lizolid (Integrace)

  • Lizomed (Aglomed)